Effect of N-acetylcysteine pretreatment of deceased organ donors on renal allograft function: A randomized controlled trial

Transplantation

Volumn 99, Issue 4, 2015, Pages 746-753

  Orban, Jean Christophe ^a   Quintard, Hervé ^a   Cassuto, Elisabeth ^b   Jambou, Patrick ^c   Samat Long, Corine ^a   Ichai, Carole ^a  

^a University Hospital of Nice University of Nice Sophia Antipolis   (France)

^b Hospital of Archet   (France)

^c NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CREATININE; NITROGEN; UREA; ANTIOXIDANT; BIOLOGICAL MARKER;

ADULT; ARTICLE; BRAIN DEATH; CADAVER DONOR; CADAVER KIDNEY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT NEPHRECTOMY; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHRECTOMY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SINGLE BLIND PROCEDURE; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; ADVERSE EFFECTS; ALLOGRAFT; BLOOD; BRAIN ANGIOGRAPHY; DONOR; DRUG ADMINISTRATION; DRUG EFFECTS; FRANCE; HEMODIALYSIS; INTRAVENOUS DRUG ADMINISTRATION; MICTURITION; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION;

ACETYLCYSTEINE; ADMINISTRATION, INTRAVENOUS; ADULT; ALLOGRAFTS; ANTIOXIDANTS; BIOMARKERS; BRAIN DEATH; CEREBRAL ANGIOGRAPHY; CREATININE; DELAYED GRAFT FUNCTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SINGLE-BLIND METHOD; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME; UP-REGULATION; URINATION;

EID: 84930178137     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000395     Document Type: Article

References (49)

1. OPTN/SRTR 2011 Annual Data Report. Available at: http://srtr.transplant. hrsa.gov/annual-reports/2011/flash/01-kidney/index.html#/1/zoomed.
2. Agence de Biomédecine Activity Report 2012. Available at: http://www. agence-biomedecine.fr/annexes/bilan2012/donnees/organes/06-rein/synthese.htm (accessed January 30, 2012).
3. Perico N, Cattaneo D, Sayegh MH, et al. Delayed graft function in kidney transplantation. Lancet. 2004;364:1814.
4. Peeters P, Vanholder R. Therapeutic interventions favorably influencing delayed and slow graft function in kidney transplantation: mission impossible?Transplantation. 2008;86:S31.
5. Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant. 2011;11:2279.
6. Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation. 1997; 63:968.
7. Tylicki L, Rutkowski B, Hörl WH. Antioxidants: a possible role in kidney protection. Kidney Blood Press Res. 2003;26(5-6):303.
8. Conesa EL, Valero F, Nadal JC, et al. N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol Regul Integr Comp Physiol. 2001;281:R730.
9. DiMari J, Megyesi J, Udvarhelyi N, et al. N-acetylcysteine ameliorates ischemic renal failure. Am J Physiol. 1997;272:F292.
10. Koning OH, Ploeg RJ, van Bockel JH, et al. Risk factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group. Transplantation. 1997;63:1620.
11. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Contrastinduced AKI. Kidney Int. 2012;2:69.
12. McCullough PA. Acute kidney injury with iodinated contrast. Crit Care Med. 2008;36:S204.
13. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1419.
14. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int. 2006;100(Suppl):S11.
15. Tapiawala S, Tinckam K, Cardella C, et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol. 2010; 21:153.
16. Yarlagadda S, Coca S, Formica RJ, et al. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009;24:1039.
17. Qureshi F, Rabb H, Kasike BL. Silent acute rejection during prolonged delayed graft function reduces kidney allograft survival. Transplantation. 2002;74:1400.
18. Sterling KA, Tehrani T, Rudnick MR. Clinical significance and preventive strategies for contrast-induced nephropathy. Curr Opin Nephrol Hypertens. 2008;17:616.
19. Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284.
20. Harrison EM, Sharpe E, Bellamy CO, et al. Heat-shock protein 90-binding agents protect renal cells from oxidative stress and reduce kidney ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2008;295:397.
21. Requiao-Moura LR, Ferraz E, Matos AC, et al. Comparison of long-term effect of thymoglobulin treatment in patients with high risk of delayed graft function. Transplant Proc. 2012;44:2429.
22. Lin A, Sekhon C, Sekhon B, et al. Attenuation of ischemia-reperfusion injury in a canine model of autologous renal transplantation. Transplantation. 2004;78:654.
23. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA. 2009;302:1067.
24. Kainz A, Wilflingseder J, Mitterbauer C, et al. Steroid pretreatment of organ donors to prevent postischemic renal allograft failure. A randomized controlled trial. Ann Intern Med. 2010;153:222.
25. Martinez F, Kamar N, Pallet N, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function. Am J Transplant. 2010;10:1704.
26. Sureshkumar KK, Hussain SM, To TY, et al. Effect of high dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol. 2012;7:1498.
27. Hosseinzadeh H, Golazri S, Abravesh M, et al. Effect of low dose dopamine on early graft function on living unrelated kidney donors. Urol J. 2012;9:389.
28. Sehirili AO, SenerG, Satiroglu H, et al. Protective effect ofN-acetylcysteine on renal ischemia/reperfusion injury in the rat. J Nephrol. 2003;16:75.
29. Dobashi K, Singh I, Orak JK, et al. Combination therapy of Nacetylcysteine, sodium nitroprusside and phosphoramidon attenuates ischemia-reperfusion injury in rat kidneys. Mol Cell Biochem. 2002;240:2.
30. Effrati S, Dishy V, AverbuckM, et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int. 2003;64; 2182.
31. Nitescu N, Ricksten SE, Marcussen N, et al. N-acetylcysteine attenuates kidney injuries in rats subjected to renal ischaemia-reperfusion. Nephrol Dial Transplant. 2006;21:1240.
32. Heyman SN, Goldfarb M, Shina A, et al. N-acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int. 2003;63:634.
33. Hoffmann U, Fischereder M, Kruger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407.
34. Moist L, Sontrop JM, Gallo K, et al. Effect of N-Acetylcysteine on serum creatinine and kidney function: results of a randomized controlled study. Am J Kidney Dis. 2010;56:643.
35. Trivedi H, Daram S, Szabi A, et al. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med2009; 122:874e9.
36. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol. 2008;3:381.
37. Brown JR, Block CA, Malenka DJ, et al. Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv. 2009;2:1116.
38. Koc F, Ozdemir K, Kata MG, et al. N-acetylcysteine plus high-dose hydration versus high-dose hydration for the prevention of contrastinduced nephropathy: CASIS-A multicenter prospective controlled trial. Int J Cardiol. 2012;155:418.
39. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Summary of recommendation statements. Kidney Int. 2012;2(suppl):8.
40. Fuller TF, Serkova N, Niemann CU, et al. Influence of donor pretreatment with N-acetylcysteine on ischemia-reperfusion injury in rat kidney grafts. J Urol. 2004;171:1296.
41. Thompson JD, Kornbrust DJ, Foy JW, et al. Toxicological and phamacokinetic properties of chemically modified siRNAs targeting p53 following intravenous administration. Nucleic Acid Ther. 2012;22:255.
42. Sener O, Tosun O. Melatonin and NAC have beneficial effects during hepatic ischemia and reperfusion. Life Sci. 2003;72:2707.
43. Montero EF, Akerahow MS. Intestinal ischemia and reperfusion injury in growing rats. Microsurgery. 2003;23:517.
44. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC trial. J Am Coll Cardiol. 2010;55:2201.
45. Johnston TD, Thacker LR, Jeon H, et al. Sensitivity of expandedcriteria donor kidneys to cold ischaemia time. Clin Transplant. 2004;18 (suppl 12):28.
46. Van Praet JT, De Vriese AS. Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens. 2007;16:336.
47. Levey AS, Bosch JP, Lewis JB, et al. Amore accuratemethod to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461.
48. Irish WD, Ilsley JN, Schnitzler MA, et al. A risk predictionmodel for delayed graft function in the current era of deceased donor renal transplantation. Am J Transplant. 2010;10:2279.
49. Metzger RA, Delmonico FL, Feng S, et al. Expanded criteria donors for kidney transplantation. Am J Transplant. 2003;3(suppl 4):114.